Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This research is being done to find how soon the liver cancer may come back and whether
proteins or genes in tumor, blood or urine can give us clues of early recurrence.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Tan Tock Seng Hospital